NextGen Scientific LLC today issued an updated announcement regarding its $10 million Regulation D, Rule 506(c) private placement offering to accredited investors, correcting inaccuracies from a prior release about the structure and use of proceeds. The company is raising funds to acquire up to 3.1% ownership in Ionics Life Sciences Limited and its subsidiaries, including Genzada Pharmaceuticals USA and Hyatt Life Sciences.
The capital will primarily support clinical and preclinical programs for Genzada’s two clinical-stage oncology drug candidates: GZ17-6.02, an oral compound being evaluated in a metastatic prostate cancer study at Virginia Commonwealth University, and GZ21T, a topical therapy for cancerous and precancerous skin conditions expected to receive regulatory approval in Q1 2026 for a Phase 1b/2a trial in actinic keratosis patients in Sweden and the Netherlands. Dr. Cameron West, Chief Operating Officer, noted promising biological effects observed in Phase I dose escalation for GZ17-6.02 and expressed optimism about GZ21T's potential for dermatologic conditions. Proceeds will also support drug manufacturing and development activities for these candidates.
Hyatt Life Sciences, a revenue-generating nutraceutical and botanical sciences enterprise, offers science-based dietary supplements and operates in the expanding global nutraceuticals market. Investors in the offering gain exposure to both clinical-stage drug development and a revenue-generating supplements business. NextGen Scientific is building a diversified healthcare platform through strategic investment in Ionics Life Sciences and its subsidiaries, aiming to generate long-term value through clinical innovation and active revenue streams. For more information, visit investinnextgen.com.
